Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Onchocerciasis 150 mcg/kg as single dose; repeat treatment every 3-12 mth until symptoms resolved. Strongyloidiasis 200 mcg/kg for 1-2 days. Topical Rosacea As 1% cream: Apply onto affected area(s) once daily for up to 4 mth, repeat treatment course if needed. Head pediculosis As 0.5% lotion: Apply sufficient amount into dry hair and scalp as single dose, then leave on for 10 min before rinsing.
Should be taken on an empty stomach. Take on an empty stomach.
Special Precautions
Patient w/ onchocerciasis and loiasis. Immunocompromised patients. Childn. Pregnancy and lactation. Patient Counselling Avoid contact w/ eyes and lips. Monitoring Parameters Assess for loiasis prior to therapy. Monitor for presence of larvae in stool, 3-4 wk post-therapy; skin and eye microfilarial counts; ophthalmological conditions.
Adverse Reactions
Significant: Mazzotti reaction (e.g. oedema, pruritus, urticaria rash, lymphadenitis, arthralgia, synovitis, fever, sore throat, cough, headache, tachycardia, orthostatic hypotension, oedema). Nervous: Dizziness, asthenia, fatigue, somnolence, vertigo, tremor. GI: Diarrhoea, abdominal pain, nausea, anorexia, constipation, vomiting. Hepatic: Increased serum ALT, AST. Haematologic: Eosinophilia, decreased WBC, increased Hb. Ophthalmologic: Conjunctivitis, ocular hyperemia, irritation (topical); limbitis, punctate opacity, abnormal sensation, eyelid oedema, anterior uveitis, conjunctival haemorrhage (oral). Dermatologic: Burning sensation, irritation, itch, dry skin, contact dermatitis, erythema (topical).
Potentially Fatal: Rarely, encephalopathy.
Drug Interactions
Increased serum concentration w/ P-glycoprotein inhibitors. Decreased serum concentration w/ P-glycoprotein inducers. Enhanced anticoagulant effect of vit K antagonists (e.g. warfarin). Diminished therapeutic effect of lactobacillus and estriol.
ATC Classification
D11AX22 - ivermectin ; Belongs to the class of other dermatologicals.
P02CF01 - ivermectin ; Belongs to the class of avermectine agents. Used as antinematodal.
Disclaimer: This information is independently developed by CIMS based on ivermectin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in